Literature DB >> 14964439

Ageing, growth hormone and physical performance.

F Lanfranco1, L Gianotti, R Giordano, M Pellegrino, M Maccario, E Arvat.   

Abstract

Human ageing is associated to a declining activity of the GH/IGF-I axis and to several changes in body composition, function and metabolism which show strict similarities with those of younger adults with pathological GH deficiency. The age-related changes of the GH/IGF-I axis activity are mainly dependent on age-related variations in the hypothalamic control of somatotroph function, which is also affected by changes in peripheral hormones and metabolic input. The term "somatopause" indicates the potential link between the age-related decline in GH and IGF-I levels and changes in body composition, structural functions and metabolism which characterise ageing. Physical exercise is an important environmental regulator of the GH/IGF-I axis activity. Increased physical fitness and regular training increase GH production in adults, while the GH response to aerobic or resistance exercise is reduced with age. In older subjects regular exercise has the potential to improve overall fitness and quality of life and is also associated to decreased morbidity and increased longevity. Similar effects are seen following GH therapy in adult deficiency. This assumption led to clinical trials focusing on rhGH and/or rhlGF-I as potential anabolic drug interventions in elderly subjects. To restore the activity of GH/IGF-I axis with anabolic, anti-ageing purposes, attention has been also paid to GH-releasing molecules such as GHRH, orally active synthetic GH-secretagogues (GHS) and, more recently, to the endogenous natural GHS, ghrelin, which exerts several important biological actions, including the regulation of metabolic balance and orexigenic effects. At present, however, there is no definite evidence that "frail" elderly subjects really benefit from restoring GH and IGF-I levels within the young adult range by treatment with rhGH, rhlGF-I, GHRH or GHS. In this article the alteration of the GH/IGF-I axis activity during ageing is revised taking into account the role of physical activity as a regulator of the axis function and considering the effects of the restoration of GH and IGF-I circulating levels on body composition and physical performance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14964439     DOI: 10.1007/BF03345237

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  117 in total

Review 1.  The exercise-induced growth hormone response in athletes.

Authors:  Richard J Godfrey; Zahra Madgwick; Gregory P Whyte
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

Review 2.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

Review 3.  The endocrinology of aging.

Authors:  S W Lamberts; A W van den Beld; A J van der Lely
Journal:  Science       Date:  1997-10-17       Impact factor: 47.728

Review 4.  Growth hormone-releasing peptides.

Authors:  E Ghigo; E Arvat; G Muccioli; F Camanni
Journal:  Eur J Endocrinol       Date:  1997-05       Impact factor: 6.664

Review 5.  Insulin-Like growth factor I: implications in aging.

Authors:  E Arvat; F Broglio; E Ghigo
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

6.  The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency.

Authors:  E R Christ; M H Cummings; N B Westwood; B M Sawyer; T C Pearson; P H Sönksen; D L Russell-Jones
Journal:  J Clin Endocrinol Metab       Date:  1997-09       Impact factor: 5.958

7.  Use of human GH in elderly patients with accidental hip fracture.

Authors:  A J Van der Lely; S W Lamberts; K W Jauch; B A Swierstra; H Hertlein; D Danielle De Vries; M A Birkett; P C Bates; W F Blum; A F Attanasio
Journal:  Eur J Endocrinol       Date:  2000-11       Impact factor: 6.664

8.  Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.

Authors:  M Maccario; E Arvat; M Procopio; L Gianotti; S Grottoli; B P Imbimbo; V Lenaerts; R Deghenghi; F Camanni; E Ghigo
Journal:  Metabolism       Date:  1995-01       Impact factor: 8.694

Review 9.  Ageing, hormones, body composition, metabolic effects.

Authors:  Alex Vermeulen
Journal:  World J Urol       Date:  2002-05       Impact factor: 4.226

Review 10.  Three-peptide control of pulsatile and entropic feedback-sensitive modes of growth hormone secretion: modulation by estrogen and aromatizable androgen.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  J Pediatr Endocrinol Metab       Date:  2003-05       Impact factor: 1.634

View more
  15 in total

Review 1.  Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies.

Authors:  Megan C Chapter; Caitlin M White; Angela DeRidder; Wayne Chadwick; Bronwen Martin; Stuart Maudsley
Journal:  Pharmacol Ther       Date:  2009-08-15       Impact factor: 12.310

Review 2.  Progesterone and vitamin d hormone as a biologic treatment of traumatic brain injury in the aged.

Authors:  Donald G Stein; Milos M Cekic
Journal:  PM R       Date:  2011-06       Impact factor: 2.298

Review 3.  Class II G protein-coupled receptors and their ligands in neuronal function and protection.

Authors:  Bronwen Martin; Rakel Lopez de Maturana; Randall Brenneman; Tom Walent; Mark P Mattson; Stuart Maudsley
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

Review 4.  Traumatic brain injury and aging: is a combination of progesterone and vitamin D hormone a simple solution to a complex problem?

Authors:  Milos Cekic; Donald G Stein
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

5.  Deafness and permanently reduced potassium channel gene expression and function in hypothyroid Pit1dw mutants.

Authors:  Mirna Mustapha; Qing Fang; Tzy-Wen Gong; David F Dolan; Yehoash Raphael; Sally A Camper; R Keith Duncan
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

6.  Body Composition, IGF1 Status, and Physical Functionality in Nonagenarians: Implications for Osteosarcopenia.

Authors:  Eleonora Poggiogalle; Katie E Cherry; L Joseph Su; Sangkyu Kim; Leann Myers; David A Welsh; S Michal Jazwinski; Eric Ravussin
Journal:  J Am Med Dir Assoc       Date:  2018-08-24       Impact factor: 4.669

Review 7.  Emerging options in growth hormone therapy: an update.

Authors:  Stephen F Kemp; J Paul Frindik
Journal:  Drug Des Devel Ther       Date:  2011-08-30       Impact factor: 4.162

8.  Carotid Intima Media Thickness Is Independently Associated with Male Gender, Middle Age, and IGF-1 in Metabolically Healthy Obese Individuals.

Authors:  Hala Abd El-Hafez; Mohamed M Elrakhawy; Azza A El-Baiomy; Mervat M El-Eshmawy
Journal:  ISRN Obes       Date:  2014-01-28

9.  Effects of Growth Hormone Administration on Muscle Strength in Men over 50 Years Old.

Authors:  A B W Tavares; E Micmacher; S Biesek; R Assumpção; R Redorat; U Veloso; M Vaisman; P T V Farinatti; F Conceição
Journal:  Int J Endocrinol       Date:  2013-12-08       Impact factor: 3.257

10.  Effect of Eurycoma longifolia standardised aqueous root extract-Physta® on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study.

Authors:  Sasikala M Chinnappan; Annie George; Pragya Pandey; Govinda Narke; Yogendra Kumar Choudhary
Journal:  Food Nutr Res       Date:  2021-05-19       Impact factor: 3.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.